The feasibility study was designed to assess Symphony tCGM System’s performance in type 1 or type 2 diabetes adult patients.

The data showed that Symphony system efficiently monitors the broad range of blood glucose values seen in people with diabetes.

Echo Therapeutics chairman and CEO Patrick Mooney said a recent, major US study showed that real-time, continuous glucose monitoring provides improved blood glucose control in type 2 diabetes, in addition to those with type 1 diabetes.

"We are extremely pleased with the outcome of the study and look forward to the continued success of our Symphony tCGM program, including the upcoming trial in critical care patients," Mooney said.